natgillin/translations-raw huggingface dataset:
The capsule has a yellow centre band, and contains yellow and purple enteric coated pellets.
Kapsula ima rumeno sredinsko črto in vsebuje rumena in vijolična zrnca z gastrorezistentno oblogo.
Elderly patients (≥65 years old) Dose adjustment is not required in elderly patients.
Starejši bolniki (stari 65 let ali več) Starejšim bolnikom odmerka ni treba prilagoditi.
Esomeprazole is extensively plasma protein bound and is therefore not readily dialysable.
Esomeprazol se v veliki meri vezže na beljakovine v plazmi in se zato ne dializira zlahka.
• If you are allergic to esomeprazole or any of the other ingredients of this medicine (listed in section 6).
- Če ste alergični na esomeprazol ali katerokoli sestavino tega zdravila (navedeno v poglavju 6).
• Do not take more than this recommended dose of one capsule (20 mg) a day, even if you don't feel an improvement immediately.
• Ne vzemite večjega odmerka od priporočenega, ki je ena kapsula (20 mg) na dan, tudi če ne čutite takoj izboljšanja.
Alternative method of taking this medicine
Drugi možni način jemanja tega zdravila
The parameters below reflect mainly the pharmacokinetics in individuals with a functional CYP2C19 enzyme, extensive metabolisers.
Spodaj navedeni parametri odražajo predvsem farmakokinetiko pri posameznikih s funkcionalnim encimom CYP2C19, tj. dobrih metabolizatorjih.
Total plasma clearance is about 17 l/h after a single dose and about 9 l/h after repeated administration.
Celotni plazemski očistek je približno 17 l/h po posamičnem odmerku in približno 9 l/h po večkratni uporabi.
These findings have no implications for the posology of esomeprazole.
Ti izsledki ne vplivajo na odmerjanje esomeprazola.
• If you are suffering from any of the side effects detailed in Section 4 which require medical attention.
• če imate katerekoli neželene učinke, opisane v poglavju 4, zaradi katerih morate poiskati zdravniško pomoč.
In healthy volunteers, concomitant administration of 40 mg esomeprazole resulted in a 32% increase in area under the plasma concentration-time curve (AUC) and a 31% prolongation of elimination half-life(t1/2) but no significant increase in peak plasma levels of cisapride.
Pri zdravih prostovoljcih je sočasna uporaba 40 mg esomeprazola povzročila 32 % povečanje površine pod krivuljo plazemske koncentracije po času (AUC) in 31 % podaljšanje eliminacijskega razpolovnega časa (t1/2), a brez pomembnega povečanja največje koncentracije cisaprida v plazmi.
Psychiatric disorders insomnia agitation, confusion, depression aggression, hallucinations
Psihiatrične motnje nespečnost agitiranost, zmedenost, depresija agresivnost, halucinacije
• Aggression
• napadalnost
If affected, patients should not drive or use machines.
Bolniki, pri katerih se pojavijo ti neželeni učinki, ne smejo voziti ali upravljati strojev.
• If you experience any of the symptoms detailed in Section 2 of this leaflet and it advises you to talk to your doctor or pharmacist.
• če se pojavijo katerikoli simptomi, opisani v poglavju 2 teh navodil za uporabo, in je navedeno, da se posvetujte z zdravnikom ali farmacevtom;
Do not take this medicine with other medicines that limit the amount of acid produced in your stomach such as proton pump inhibitors (e.g. pantoprazole, lansoprazole, rabeprazole or omeprazole) or an H2 antagonist (e.g. ranitidine or famotidine).
Ne jemljite tega zdravila z drugimi zdravili, ki zmanjšujejo nastajanje kisline v želodcu, npr. z zaviralcem protonske črpalke (na primer s pantoprazolom, lansoprazolom, rabeprazolom ali omeprazolom) ali antagonistom receptorjev H2 (na primer z ranitidinom, famotidinom).
Thus, when esomeprazole is combined with medicinal products metabolised by CYP2C19, such as warfarin, phenytoin, citalopram, imipramine, clomipramine, diazepam, etc., the plasma concentrations of these medicinal products may be increased and a dose reduction could be needed.
Če je torej esomeprazol uporabljen v kombinaciji z zdravili, ki se presnavljajo s CYP2C19, npr. z varfarinom, fenitoinom, citalopramom, imipraminom, klomipraminom, diazepamom itn., se lahko koncentracija teh zdravil v plazmi zviša in potrebno je lahko zmanjšanje odmerka.
lansoprazole, rabeprazole or omeprazole).
lansoprazol, rabeprazol ali omeprazol).
• Low numbers of red blood cells, white blood cells, and platelets (a condition called pancytopenia).
• majhno število rdečih krvnih celic, belih krvnih celic in krvnih ploščic (takšno stanje imenujemo pancitopenija)
• You are taking any medicines listed in the package leaflet.
• jemljete katerakoli zdravila, ki so navedena v navodilu za uporabo;
The absorption of medicinal products taken orally such as ketoconazole, itraconazole and erlotinib can decrease during treatment with esomeprazole and the absorption of digoxin can increase during treatment with esomeprazole.
Absorpcija peroralnih zdravil, kot so ketokonazol, itrakonazol in erlotinib, se lahko med zdravljenjem z esomeprazolom zmanjša, absorpcija digoksina pa se lahko med zdravljenjem z esomeprazolom poveča.
In two multicentre, randomised, double-blind, placebo-controlled pivotal studies 234 subjects with a recent history of frequent heartburn were treated with 20 mg esomeprazole for 4 weeks.
V dveh multicentričnih, randomiziranih, dvojno slepih, s placebom kontroliranih ključnih študijah je 234 preiskovancev z nedavno anamnezo pogoste zgage 4 tedne prejemalo 20 mg esomeprazola.
dry mouth stomatitis, gastrointestinal candidiasis microscopic colitis
suha usta stomatitis, gastrointestinalna kandidoza mikroskopski kolitis
Patients with long-term recurrent symptoms of indigestion or heartburn should see their doctor at regular intervals.
Bolniki, ki imajo dolgotrajne ponavljajoče se simptome težav z želodcem ali zgago, morajo hoditi na redne preglede k zdravniku.
For 20 mg esomeprazole the corresponding values are 50% and 68% respectively.
Za 20-mg odmerek esomeprazola sta ti vrednosti 50 % oz. 68 %.
The bottle also contains a sealed container with silica gel desiccant.
Plastenka vsebuje tudi zapečaten vsebnik s sušilom iz silikagela.
This medicinal product contains sugar spheres (sucrose).
To zdravilo vsebuje sladkorne kroglice (saharozo).
The remaining part is dependent on another specific isoform, CYP3A4, responsible for the formation of esomeprazole sulphone, the main metabolite in plasma.
Preostali del je odvisen od druge specifične izooblike, CYP3A4; CYP3A4 je odgovoren za tvorbo esomeprazolsulfona, glavnega presnovka esomeprazola v plazmi.
• You are due to have an endoscopy or a urea breath test.
• ste naročeni na endoskopijo ali dihalni test s sečnino,
This time and dose-dependency is due to a decrease of first pass metabolism and systemic clearance probably caused by an inhibition of the CYP2C19 enzyme by esomeprazole and/or its sulphone metabolite.
Ta odvisnost od časa in odmerka je posledica manjše presnove prvega prehoda in sistemskega očistka esomeprazola; vzrok je verjetno zavrtje encima CYP2C19 z esomeprazolom in/ali njegovim sulfonskim presnovkom.
Keep the container tightly closed to protect from moisture.
Vsebnik shranjujte tesno zaprt za zagotovitev zaščite pred vlago.
If you take more Nexium Control than you should If you take more Nexium Control than recommended, talk to your doctor or pharmacist straight away.
Če ste vzeli večji odmerek zdravila Nexium Control, kot je priporočeno, se takoj posvetujte z zdravnikom ali farmacevtom.
Other secondary endpoints were supportive of the primary endpoint, including relief of heartburn at week 1 and week 2, percentage of 24 hour days without heartburn at week 1 and week 2, mean heartburn severity at week 1 and week 2, and time to initial and sustained resolution of heartburn over a 24 hour period and during the night compared to placebo.
Drugi sekundarni opazovani dogodki študije so podprli primarnega, vključno z olajšanjem zgage po enem in dveh tednih, odstotkom 24-urnih dni brez zgage po enem in dveh tednih, povprečno vrednostjo resnosti zgage po enem in dveh tednih ter časom do prvotnega in trajnega prenehanja zgage v 24-urnem obdobju in ponoči v primerjavi s placebom.
Concomitant treatment with omeprazole (20 mg daily) and digoxin in healthy subjects increased the bioavailability of digoxin by 10% (up to 30% in two out of ten subjects).
Sočasno zdravljenje z omeprazolom (20 mg na dan) in digoksinom je pri zdravih preiskovancih povečalo biološko uporabnost digoksina za 10 % (do 30 % pri dveh od desetih preiskovancev).
Excipient(s) with known effect Each gastro-resistant hard capsule contains 11.5 mg sucrose.
Pomožne snovi z znanim učinkom: Ena trda gastrorezistentna kapsula vsebuje 11,5 mg saharoze.
Do not take this medicine if you are also taking a medicine containing nelfinavir (used to treat HIV infection).
Ne jemljite tega zdravila, če sočasno jemljete zdravilo, ki vsebuje nelfinavir (uporablja se za zdravljenje okužbe s HIV).
In vivo conversion to the R-isomer is negligible.
Njegova pretvorba v R-izomer je in vivo zanemarljiva.
• Disturbed sleep (insomnia), feeling sleepy.
• moten spanec (nespečnost), zaspanost
Food intake both delays and decreases the absorption of esomeprazole although this has no significant influence on the effect of esomeprazole on intragastric acidity.
Uživanje hrane upočasni in zmanjša absorpcijo esomeprazola, vendar to bistveno ne vpliva na učinek zdravila na kislost v želodcu.
No dose-related adverse reactions have been identified.
Z odmerkom povezanih neželenih učinkov niso ugotovili.
Using AUC as a surrogate parameter for plasma concentration, a relationship between inhibition of acid secretion and exposure has been shown.
Z uporabo AUC kot nadomestnega parametra za koncentracijo v plazmi so ugotovili, da sta zavrtje izločanja kisline in izpostavljenosti zdravilu povezana.
There is very limited experience to date with deliberate overdose.
Izkušnje z namernim prevelikim odmerjanjem zdravila so zelo omejene.
The symptoms described in connection with 280 mg esomeprazole were gastrointestinal symptoms and weakness.
Pri odmerku 280 mg esomeprazola so bili opisani gastrointestinalni simptomi in šibkost.
• You have had a stomach ulcer or stomach surgery in the past.
• ste v preteklosti kdaj imeli razjedo na želodcu ali operacijo želodca,
Reflux is the backflow of acid from the stomach into the gullet (“foodpipe”) which may become inflamed and painful.
"Refluks" pomeni vračanje kisline iz želodca nazaj v požiralnik, ki se zaradi tega lahko vname in boli.
After oral dosing with esomeprazole 20 mg and 40 mg the onset of effect occurs within one hour.
Po peroralni uporabi 20 mg ali 40 mg esomeprazola se učinek pojavi v eni uri.
Indigo carmine (E132) Erythrosine (E127) Allura red AC (E129)
Ovojnica kapsule želatina indigo karmin (E132) eritrozin (E127) alura rdeče AC (E129)
You may experience symptoms such as diarrhoea, stomach ache, constipation, feeling or being sick and weakness.
Pojavijo se lahko simptomi kot so driska, bolečine v želodcu, zaprtost, siljenje na bruhanje ali bruhanje in šibkost.
The investigators' assessments of heartburn resolution were consistent with the subjects' assessments, showing statistically significant differences between esomeprazole (34.7% - 41.8%) compared to placebo (8.0% - 11.4%).
Ocene prenehanja zgage, ki so jih podali raziskovalci, so se ujemale z ocenami preiskovancev, kar kaže na statistično pomembne razlike med esomeprazolom (34,7-41,8 %) in placebom (8,0-11,4 %).
• Low levels of sodium in the blood.
• nizka koncentracija natrija v krvi.
The major part of the metabolism of esomeprazole is dependent on the polymorphic CYP2C19, responsible for the formation of the hydroxy- and desmethyl metabolites of esomeprazole.
Glavni del presnove esomeprazola je odvisen od polimorfizma CYP2C19, ki je odgovoren za tvorbo hidroksi- in demetiliranih presnovkov esomeprazola.
• Blood problems such as a reduced number of white blood cells or platelets.
• krvne motnje, npr. zmanjšanje števila belih krvnih celic (levkocitov) ali krvnih ploščic
Effects of esomeprazole on the pharmacokinetics of other medicinal products As esomeprazole is one enantiomer of omeprazole it is reasonable to advise about interactions reported with omeprazole.
Učinki esomeprazola na farmakokinetiko drugih zdravil Esomeprazol je enantiomer omeprazola, zato je upravičeno opozoriti na medsebojna delovanja, opisana pri omeprazolu.
When starting or ending treatment with esomeprazole, the potential for interactions with medicinal products metabolised through CYP2C19 should be considered.
Na začetku in na koncu zdravljenja z esomeprazolom je treba upoštevati možnost medsebojnega delovanja z zdravili, ki se presnavljajo s CYP2C19.
• You have jaundice (yellowing of skin or eyes) or severe liver problems.
• imate zlatenico (porumenelost kože ali očesnih beločnic) ali hudo okvaro jeter,
Other possible interaction mechanisms are via inhibition of CYP2C19.
Drugi možni mehanizmi medsebojnega delovanja so prek zavrtja CYP2C19.
Nexium Control contains sugar spheres, which contain sucrose, a type of sugar.
Zdravilo Nexium Control vsebuje sladkorne kroglice, ki vsebujejo saharozo (vrsta sladkorja).
If the combination of atazanavir with a PPI is judged unavoidable, close clinical monitoring is recommended in combination with an increase in the dose of atazanavir to 400 mg with 100 mg of ritonavir.
Če se sočasni uporabi atazanavirja in zaviralca protonske črpalke ni mogoče izogniti, sta priporočljiva natančen klinični nadzor ter povečanje odmerka atazanavirja na 400 mg s 100 mg ritonavirja.
Investigated medicinal products with no clinically relevant interaction Amoxicillin and quinidine
Preiskovana zdravila brez klinično pomembnih interakcij Amoksicilin in kinidin
The absolute bioavailability is 64% after a single dose of 40 mg and increases to 89% after repeated once-daily administration.
Absolutna biološka uporabnost po posamičnem 40-mg odmerku je 64 %, po večkratnem odmerjanju enkrat na dan pa se poveča na 89 %.
• Cilostazol (used to treat intermittent claudication - a condition where poor blood supply to the leg muscles causes pain and difficulty in walking)
• cilostazol (uporablja se za zdravljenje intermitentne klavdikacije - stanje, kjer nezadosten dotok krvi v mišice nog povzroči bolečine in težave pri hoji)
This can cause weakness, bruising or make infections more likely.
Posledice so lahko šibkost, podplutbe ali večja verjetnost okužb.
However, side effects such as dizziness and visual disturbances may uncommonly occur (see section 4).
Kljub temu pa se lahko občasno pojavijo neželeni učinki kot so omotica in motnje vida (glejte poglavje 4).
In case of clopidogrel, a prodrug which is transformed into its active metabolite via CYP2C19, the plasma concentrations of the active metabolite may be decreased.
V primeru klopidogrela, ki je predzdravilo in se presnovi v aktivni presnovek s pomočjo CYP2C19, je koncentracija aktivnega metabolita v plazmi lahko zmanjšana.
• You may need to take the capsules for 2 or 3 days in a row before your reflux symptoms (for example, heartburn and acid regurgitation) get better.
• Morda boste morali kapsule jemati 2 ali 3 dni zapored, preden se vam simptomi refluksa (na primer, zgaga ali regurgitacija kisline) izboljšajo.
• Enlarged breasts in men
• povečanje dojk pri moških
The CYP2C19 and CYP3A4 inhibitor voriconazole increased omeprazole AUCt by 280%.
Zaviralec CYP2C19 in CYP3A4 vorikonazol je povečal AUCt omeprazola za 280 %.
It is unknown whether esomeprazole/metabolites are excreted in human milk.
Ni znano, ali se esomeprazol ali njegovi presnovki pri človeku izločajo v materino mleko.
Concomitant administration of 30 mg esomeprazole resulted in a 45% decrease in clearance of the CYP2C19 substrate diazepam.
Sočasna uporaba 30 mg esomeprazola je za 45 % zmanjšala očistek diazepama, ki je substrat CYP2C19.
Non-clinical data reveal no particular hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, and toxicity to reproduction and development.
Predklinični podatki na osnovi običajnih študij farmakološke varnosti, toksičnosti pri ponavljajočih se odmerkih, genotoksičnosti in toksičnosti za reprodukcijo in razvoj ne kažejo posebnega tveganja za človeka.
What Nexium Control is and what it is used for
Kaj je zdravilo Nexium Control in za kaj ga uporabljamo
Increased gastric pH during omeprazole treatment may change the absorption of the protease inhibitors.
Zvišanje želodčnega pH med zdravljenjem z omeprazolom lahko spremeni absorpcijo zaviralcev proteaz.
The glass should be rinsed with half a glass of water and the water drunk.
Kozarec je nato treba splakniti s pol kozarca vode in to vodo popiti.
Blood and lymphatic system disorders leukopenia, thrombocytopenia agranulocytosis, pancytopenia
Bolezni krvi in limfatičnega sistema levkopenija, trombocitopenija agranulocitoza, pancitopenija
• You may need to take the tablets for 2 or 3 days in a row before your reflux symptoms (for example, heartburn and acid regurgitation) get better.
• Morda boste morali tablete jemati 2 ali 3 dni zapored, preden se vam simptomi refluksa (na primer, zgaga ali regurgitacija kisline) izboljšajo.
In high-dose methotrexate administration a temporary withdrawal of esomeprazole may need to be considered.
Med visokoodmernim zdravljenjem z metotreksatom je lahko potrebno prehodno prenehanje uporabe esomeprazola.
After repeated once-daily administration of 40 mg esomeprazole, the mean area under the plasma concentration-time curve was approximately 100% higher in poor metabolisers than in subjects having a functional CYP2C19 enzyme (extensive metabolisers).
Po ponavljajoči se uporabi 40 mg esomeprazola, enkrat na dan, je povprečna površina pod krivuljo plazemske koncentracije po času pri slabih metabolizatorjih približno 100 % večja kot pri osebah s funkcionalnim encimom CYP2C19 (dobrih metabolizatorjih).
Mean peak plasma concentrations were 60% higher.
Povprečna največja koncentracija v plazmi je 60 % večja.
Esomeprazole must not be used concomitantly with nelfinavir (see section 4.5).
Esomeprazola se ne sme uporabljati sočasno z nelfinavirjem (glejte poglavje 4.5).
• Yellow skin, dark urine and tiredness, which can be symptoms of liver problems, seen rarely.
• porumenelost kože, temen urin in utrujenost; to so lahko simptomi težav z jetri, pojavijo se redko
Omeprazole (40 mg once daily) increased voriconazole (a CYP2C19 substrate) Cmax and AUCτ by 15% and 41%, respectively.
Omeprazol (40 mg enkrat na dan) je povečal Cmax vorikonazola (substrata CYP2C19) za 15 % in njegovo AUCτ za 41 %.
Other medicines and Nexium Control
Druga zdravila in zdravilo Nexium Control
Carcinogenicity studies in the rat with the racemic mixture have shown gastric ECL-cell hyperplasia and carcinoids.
Pri podganah so študije kancerogenosti z uporabo racemne mešanice pokazale hiperplazijo želodčnih enterokromafinim podobnih celic in karcinoide.
In both studies esomeprazole 20 mg was significantly better compared to placebo for the primary endpoint, complete resolution of heartburn, defined as no heartburn episodes during the last 7 days prior to the final visit (33.9% - 41.6% vs. placebo 11.9 - 13.7%, (p<0.001).
V obeh študijah je bil esomeprazol 20 mg pomembno boljši v primerjavi s placebom pri primarnem opazovanem dogodku, popolnem prenehanju zgage, opredeljenem kot odsotnost epizod zgage v zadnjih 7 dneh pred končnim obiskom (33,9-41,6 % v primerjavi s placebom 11,9-13,7 % (p < 0,001)).
Approximately 78% of the subjects on 20 mg esomeprazole reported first resolution of heartburn within the first week of treatment compared to 52 - 58% for placebo.
Približno 78 % preiskovancev, ki so dobivali 20 mg esomeprazola, je poročalo o prvem prenehanju zgage v prvem tednu zdravljenja v primerjavi z 52-58 % preiskovancev, ki so dobivali placebo.
Treatment with proton pump inhibitors (PPIs) may lead to a slightly increased risk of gastrointestinal infections such as Salmonella and Campylobacter and in hospitalised patients, also possibly Clostridium difficile (see section 5.1).
Zdravljenje z zaviralci protonske črpalke lahko rahlo poveča tveganje za okužbe prebavil, npr. z bakterijami Salmonella in Campylobacter ter pri hospitaliziranih bolnikih morda tudi s Clostridium difficile (glejte poglavje 5.1).
• Diazepam (used to treat anxiety, relax muscles or in epilepsy)
• diazepam (uporablja se za zdravljenje tesnobnosti, za sproščanje mišic ali pri epilepsiji)
Esomeprazole has been shown to have no clinically relevant effects on the pharmacokinetics of amoxicillin and quinidine.
Esomeprazol nima klinično pomembnega učinka na farmakokinetiko amoksicilina in kinidina.
Animal studies with the racemic mixture omeprazole, given by oral administration do not indicate effects with respect to fertility.
Študije na živalih, v katerih so uporabljali racemno mešanico omeprazola peroralno, niso pokazale vplivov na plodnost.
Effects of other medicinal products on the pharmacokinetics of esomeprazole Medicinal products which inhibit CYP2C19 and/or CYP3A4
Učinki drugih zdravil na farmakokinetiko esomeprazola Zdravila, ki zavirajo CYP2C19 in/ali CYP3A4
However, caution should be exercised when esomeprazole is given at high doses in elderly patients.
Vendar pa je v primeru uporabe velikih odmerkov esomeprazola pri starejših bolnikih potrebna previdnost.
There is no relevant use of Nexium Control in the paediatric population below 18 years of age for the indication of “short-term treatment of reflux symptoms (e.g., heartburn and acid regurgitation)”.
Zdravilo Nexium Control ni namenjeno za uporabo pri pediatrični populaciji, mlajši od 18 let, za indikacijo “kratkotrajnega zdravljenja simptomov refluksa (npr. zgage in regurgitacije kisline)”.
No studies have been performed in patients with decreased renal function.
Študij pri bolnikih z zmanjšanim delovanjem ledvic ni bilo.
High-density polyethylene (HDPE) bottle with an induction seal closure and child resistant closure containing 14 gastro-resistant capsules.
Plastenka iz polietilena visoke gostote (HDPE) z indukcijsko zaporko s tesnilom in za otroke varno zaporko, ki vsebuje 14 gastrorezistentnih kapsul.
The plasma elimination half-life is about 1.3 hours after repeated once-daily dosing.
Plazemski eliminacijski razpolovni čas po večkratnem odmerjanju enkrat na dan je okrog 1,3 ure.
Patients should not take another PPI or H2 antagonist concomitantly.
Bolniki sočasno ne smejo jemati kakšnega drugega zaviralca protonske črpalke ali antagonista histaminskih receptorjev H2.
Elderly patients (≥65 years old) The metabolism of esomeprazole is not significantly changed in elderly patients (71-80 years of age).
Starejši bolniki (stari 65 let ali več) Pri starejših osebah (71-80 let) presnova esomeprazola ni bistveno spremenjena.
Excipient(s) with known effect Each gastro-resistant tablet contains 28 mg sucrose.
Pomožne snovi z znanim učinkom: Ena gastrorezistentna tableta vsebuje 28 mg saharoze.
Nexium Control is available in pack sizes of 7 and 14 gastro-resistant tablets in blisters.
Zdravilo Nexium Control je na voljo v velikostih pakiranj s 7 in 14 gastrorezstentnimi tabletami v pretisnih omotih.
Esomeprazole 20 mg has been demonstrated to effectively treat frequent heartburn in subjects receiving one dose per 24 hours over 2 weeks.
Dokazali so, da 20 mg esomeprazola učinkovito zdravi pogosto zgago pri preiskovancih, ki so 2 tedna dobivali en odmerek na 24 ur.
Pack sizes of 7 and 14 gastro-resistant tablets.
Velikosti pakiranj s 7 in 14 gastrorezistentnimi tabletami.
• You have been taking treatment continuously for reflux or heartburn for 4 or more weeks.
• jemljete zdravilo proti refluksu ali zgagi nepretrgoma že 4 tedne ali več,
Following a single dose of 40 mg esomeprazole the mean are under the plasma concentration-time curve is approximately 30% higher in females than in males.
Po enkratnem odmerku 40 mg esomeprazola je povprečna površina pod krivuljo plazemske koncentracije po času pri ženskah približno 30 % večja kot pri moških.
Treatment with PPIs may lead to slightly increased risk of gastrointestinal infections such as Salmonella and Campylobacter and in hospitalised patients, also possibly Clostridium difficile.
Zdravljenje z zaviralci protonske črpalke lahko rahlo poveča tveganje okužb prebavil, npr. z bakterijami, kakršne so Salmonella in Campylobacter, pri hospitaliziranih bolnikih pa morda tudi s Clostridium difficile.